stockrow
Saturday 7 November 2026
Export VSTM’s income statement to Excel — free account
Verastem, Inc.
VSTM Healthcare Biotechnology
Verastem, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 209.1% from fiscal 2024.
- Revenue
- +113.6%
- EPS
- +45.2%
- Free cash flow
- +24.5%
- Total debt
- +52.9%
Quarter to September 2026, against a year earlier
8.43
0.95
−10.13%
Follow VSTM
Alert me
Verastem, Inc. (VSTM) P/E ratio
Verastem, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RAPP Rapport Therapeutics, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| VSTM Verastem, Inc. | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| INBX Inhibrx Biosciences, Inc. compare | n/m |
| MNKD MannKind Corporation compare | n/m |
| SPTX Seaport Therapeutics, Inc compare | n/m |
| SGP SpyGlass Pharma, Inc. compare | n/m |
| AVLN Avalyn Pharma Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)